Marietta Kirchner

Generating author description...

All published works

Action	Title	Year	Authors
+	drugdevelopR: Planning of phase II/III drug development programs with optimal sample size allocation and Go/No-go decision rules in R	2025	Johannes Cepicka Lukas D. Sauer Marietta Kirchner Meinhard Kieser Stella Erdmann
+ PDF Chat	Optimal sample size allocation for two‐arm superiority and non‐inferiority trials with binary endpoints	2024	Marietta Kirchner Stefanie Schüpke Meinhard Kieser
+	Drugdevelopr: Planning of Phase Ii/Iii Drug Development Programs with Optimal Sample Size Allocation and Go/No-Go Decision Rules in R	2024	Johannes Cepicka Lukas D. Sauer Marietta Kirchner Meinhard Kieser Stella Erdmann
+	Estimation of treatment effects in early-phase randomized clinical trials involving external control data	2023	Heiko Götte Marietta Kirchner Johannes Krisam Arthur Allignol Armin Schüler Meinhard Kieser
+	An adaptive design for early clinical development including interim decision for single‐arm trial with external controls or randomized trial	2022	Heiko Götte Marietta Kirchner Johannes Krisam Arthur Allignol François-Xavier Lamy Armin Schüler Meinhard Kieser
+	Estimands—a basic element for clinical trials. Part 29 of a series on evaluation of scientific publications	2021	Moritz Pohl Lukas Baumann Rouven Behnisch Marietta Kirchner Johannes Krisam Anja Sander
+ PDF Chat	Optimal designs for phase II/III drug development programs including methods for discounting of phase II results	2020	Stella Erdmann Marietta Kirchner Heiko Götte Meinhard Kieser
+	Optimal decision‐making in oncology development programs based on probability of success for phase <scp>III</scp> utilizing phase <scp>II</scp>/<scp>III</scp> data on response and overall survival	2020	Heiko Götte Junyuan Xiong Marietta Kirchner Hakan Demirtaş Meinhard Kieser
+ PDF Chat	Optimal Designs for Multi-Arm Phase II/III Drug Development Programs	2019	Stella Preussler Marietta Kirchner Heiko Götte Meinhard Kieser
+ PDF Chat	Adjustment for exploratory cut‐off selection in randomized clinical trials with survival endpoint	2019	Heiko Götte Marietta Kirchner Meinhard Kieser
+	Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed	2018	Stella Preussler Meinhard Kieser Marietta Kirchner
+	Optimal planning of phase II/III programs for clinical trials with multiple endpoints	2018	Meinhard Kieser Marietta Kirchner Eva Dölger Heiko Götte
+	Simulation-based adjustment after exploratory biomarker subgroup selection in phase II	2017	Heiko Götte Marietta Kirchner Martin Oliver Sailer Meinhard Kieser
+	Probability of success for phase III after exploratory biomarker analysis in phase II	2017	Heiko Götte Marietta Kirchner Martin Oliver Sailer
+	Sample size planning for phase II trials based on success probabilities for phase III	2015	Heiko Götte Armin Schüler Marietta Kirchner Meinhard Kieser
+	Utility‐based optimization of phase II/III programs	2015	Marietta Kirchner Meinhard Kieser Heiko Götte Armin Schüler
+	A multiple filter test for the detection of rate changes in renewal processes with varying variance	2014	Michael Messer Marietta Kirchner Julia Schiemann Jochen Roeper Ralph Neininger Gaby Schneider
+	A multiple filter test for change point detection in renewal processes with varying variance	2013	Michael Messer Marietta Kirchner Julia Schiemann Jochen Roeper Ralph Neininger Gaby Schneider

Common Coauthors

Coauthor	Papers Together
Meinhard Kieser	14
Heiko Götte	11
Armin Schüler	4
Stella Erdmann	3
Johannes Krisam	3
Lukas D. Sauer	2
Michael Messer	2
Martin Oliver Sailer	2
Ralph Neininger	2
Arthur Allignol	2
Jochen Roeper	2
Julia Schiemann	2
Johannes Cepicka	2
Gaby Schneider	2
Stella Preussler	2
Anja Sander	1
Stefanie Schüpke	1
Moritz Pohl	1
Eva Dölger	1
François-Xavier Lamy	1
Junyuan Xiong	1
Rouven Behnisch	1
Hakan Demirtaş	1
Lukas Baumann	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Assurance in clinical trial design	2005	Anthony O’Hagan John Stevens Michael J. Campbell	9
+	Sample size planning for phase II trials based on success probabilities for phase III	2015	Heiko Götte Armin Schüler Marietta Kirchner Meinhard Kieser	8
+	Discounting phase 2 results when planning phase 3 clinical trials	2012	Simon Kirby James R. Burke Christy Chuang‐Stein Chanthy Sin	6
+	Adapting by calibration the sample size of a phase III trial on the basis of phase II data	2010	Daniele De Martini	6
+	Sample size and the probability of a successful trial	2006	Christy Chuang‐Stein	6
+	The asymptotic properties of nonparametric tests for comparing survival distributions	1981	David Schoenfeld	6
+ PDF Chat	Adapting the sample size planning of a phase III trial based on phase II data	2006	Sue‐Jane Wang Hung Hung Robert T. O’Neill	5
+	Utility‐based optimization of phase II/III programs	2015	Marietta Kirchner Meinhard Kieser Heiko Götte Armin Schüler	5
+ PDF Chat	Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer	2012	Hui Gan Benoît You Gregory R. Pond E. X. Chen	5
+ PDF Chat	Bayesian cost‐effectiveness analysis from clinical trial data	2001	Anthony O’Hagan John Stevens Jacques Montmartin	4
+	Assessing the success probability of a Phase III clinical trial based on Phase II data	2010	Zheng Su	4
+	A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion	1986	David J. Spiegelhalter Laurence S. Freedman	4
+	Bayesian Approaches to Randomized Trials	1994	David J. Spiegelhalter Laurence S. Freedman Mahesh Parmar	3
+	Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness—one larger vs two smaller pivotal studies by Z. Shun, E. Chi, S. Durrleman and L. Fisher, <i>Statistics in Medicine</i> 2005; <b>24</b>:1619–1637	2005	Gary G. Koch	3
+ PDF Chat	Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012	2014	Nicholas S. Downing Jenerius A. Aminawung Nilay D. Shah Harlan M. Krumholz Joseph S. Ross	3
+	RECONSIDERING SOME ASPECTS OF THE TWO-TRIALS PARADIGM	2002	Jeff Maca P. Gallo Michael Branson Willi Maurer	3
+	A Revisit of Sample Size Decisions in Confirmatory Trials	2010	Christy Chuang‐Stein Ruoyong Yang	3
+	A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs	2007	Nitin R. Patel Suresh Ankolekar	3
+	Stopping rules and estimation problems in clinical trials	1988	Michael D. Hughes Stuart J. Pocock	3
+	Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness—one larger vs two smaller pivotal studies	2004	Zhenming Shun Eric Chi Sylvain Durrleman Lloyd D. Fisher	3
+	Optimal Sample Sizes and Go/No-Go Decisions for Phase II/III Development Programs Based on Probability of Success	2011	Kaihong Jiang	3
+ PDF Chat	Bayesian Optimal Design for Phase II Screening Trials	2007	Meichun Ding Gary L. Rosner Peter Müller	3
+ PDF Chat	A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk	2013	Nitin R. Patel Suresh Ankolekar Zoran Antonijevic Natasa Rajicic	3
+ PDF Chat	Optimal Designs for Multi-Arm Phase II/III Drug Development Programs	2019	Stella Preussler Marietta Kirchner Heiko Götte Meinhard Kieser	3
+	Conditional Bias of Point Estimates Following a Group Sequential Test	2004	Xiaoyin Fan David L. DeMets K. K. Gordon Lan	3
+	The shrinking or disappearing observed treatment effect	2014	Christy Chuang‐Stein Simon Kirby	3
+	Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed	2018	Stella Preussler Meinhard Kieser Marietta Kirchner	3
+	Key multiplicity issues in clinical drug development	2012	Alex Dmitrienko Ralph B. D’Agostino Mohammad F. Huque	3
+	One Large, Well-Designed, Multicenter Study as an Alternative to the Usual Fda Paradigm	1999	Lloyd D. Fisher	3
+ PDF Chat	Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America	2007	Walter Offen Christy Chuang‐Stein Alex Dmitrienko Gary S. Littman Jeff Maca Laura A. Meyerson Robb J. Muirhead Paul Stryszak Alex Baddy Kun Chen	3
+	Multi-State Models for Panel Data: The<b>msm</b>Package for<i>R</i>	2011	Christopher Jackson	2
+ PDF Chat	Matching Methods for Causal Inference: A Review and a Look Forward	2010	Elizabeth A. Stuart	2
+ PDF Chat	The relationship between the power prior and hierarchical models	2006	Ming‐Hui Chen Joseph G. Ibrahim	2
+	Computation of Multivariate Normal and t Probabilities	2009	Alan Genz Frank Bretz	2
+	An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints†	2010	Martin Jenkins Andrew Stone Christopher Jennison	2
+	The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme	2006	Karla V. Ballman Jan C. Buckner Paul D. Brown Caterina Giannini Patrick J. Flynn Betsy LaPlant Kurt A. Jaeckle	2
+ PDF Chat	A Quantitative Process for Enhancing End of Phase 2 Decisions	2013	Tony Sabin James Matcham Sarah Bray Andrew Copas Mahesh Parmar	2
+	The role of the minimum clinically important difference and its impact on designing a trial	2010	Christy Chuang‐Stein Simon Kirby Ian Hirsch Gary Atkinson	2
+	Randomized Phase II Trials: Inevitable or Inadvisable?	2010	Hui Gan Axel Grothey Gregory R. Pond Malcolm J. Moore Lillian L. Siu Daniel J. Sargent	2
+ PDF Chat	Use of historical control data for assessing treatment effects in clinical trials	2013	Kert Viele Scott Berry Beat Neuenschwander Billy Amzal Fang Chen Nathan Enas Brian P. Hobbs Joseph G. Ibrahim Nelson Kinnersley Stacy Lindborg	2
+	Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information	2014	Kaspar Rufibach Paul Jordan Markus Abt	2
+	Sample size calculation for the log-rank tests for multi-arm trials with a control	2008	Sin‐Ho Jung Choong-Rak Kim Shein‐Chung Chow	2
+ PDF Chat	A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models	2002	Alan E. Gelfand Fei Wang	2
+	Bootstrap corrections of treatment effect estimates following selection	2013	G. Rosenkranz	2
+ PDF Chat	Approximate Bayesian Computation	2013	Mikael Sunnåker Alberto Giovanni Busetto Elina Numminen Jukka Corander Matthieu Foll Christophe Dessimoz	2
+	Decision Making from Phase II to Phase III and the Probability of Success: Reassured by “Assurance”?	2013	Kevin J. Carroll	2
+	Accounting for Variability in Sample Size Estimation with Applications to Nonadherence and Estimation of Variance and Effect Size	2006	Michael P. Fay M. Elizabeth Halloran Dean Follmann	2
+	Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer	2003	Patrick Royston Mahesh Parmar Wendi Qian	2
+	A Bayesian Approach to Subgroup Identification	2014	James O. Berger Xiaojing Wang Lei Shen	2
+	Categorical Data Analysis	2002	Alan Agresti	2